Get started
Author

Shigenori E. Nagai

Observed names: Nagai, Shigenori, Nagai,Shigenori E., S Nagai, S. E. Nagai, S. Nagai, SHIGENORI E. NAGAI, Shigenori E Nagai, Shigenori Nagai
ORCID: 0000-0003-2887-6066
Observed ORCID: 0000-0003-2887-6066
OpenAlex ID: A5102906856
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
2019 · Yasuhiro Fujiwara, Hirofumi Mukai, et al. · British Journal of Cancer · 156
PDF
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition
2016 · Tomohiko Aihara, Tatsuya Toyama, et al. · Breast Cancer · 88
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
2020 · Tatsunori Shimoi, Shigenori E. Nagai, et al. · Breast Cancer · 73
PDF
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
2023 · Mitsuo Terada, Aki Ito, et al. · Breast Cancer · 71
PDF
Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer
2012 · YUJI HAYASHI, HIROYUKI TAKEI, et al. · Oncology Letters · 64
PDF
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
2017 · José Baselga, Claudio Zamagni, et al. · Clinical Breast Cancer · 52
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)
2014 · M. Takada, H. Ishiguro, et al. · Breast Cancer Research and Treatment · 42
PDF
Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan
2017 · M. J. Fischer, K. Inoue, et al. · Breast Cancer Research and Treatment · 35
PDF
Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
2010 · Hiroyuki Takei, Masafumi Kurosumi, et al. · Breast Cancer · 25
Impact of immediate breast reconstruction on postoperative adjuvant chemotherapy: a single center study
2013 · Atsumori Hamahata, Kazuyuki Kubo, et al. · Breast Cancer · 24
Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies
2009 · Hiroyuki Takei, Masafumi Kurosumi, et al. · Breast Cancer · 24
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
2022 · Takayuki Ueno, Shigehisa Kitano, et al. · BMC Medicine · 21
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
2021 · Norikazu Masuda, Hiroko Bando, et al. · Breast Cancer Research and Treatment · 20
PDF
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study
2024 · Tetsuhiro Yoshinami, Shigenori E. Nagai, et al. · Breast Cancer · 19
PDF
A Phase III Randomized, Double-Blind, Trial Comparing Sorafenib Plus Capecitabine Versus Placebo Plus Capecitabine in the Treatment of Locally Advanced or Metastatic Her2-Negative Breast Cancer (Resilience)
2014 · J. Baselga, C. Zamagni, et al. · Annals of Oncology · 19
Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation
2012 · Hiroyuki Takei, Takashi Yoshida, et al. · International Journal of Clinical Oncology · 18
Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues
2003 · Yutaka Yamamoto, Jun-Ichi Yamashita, et al. · Oncology Reports · 18
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment
2024 · Yutaka Yamamoto, Chikako Yamauchi, et al. · Breast Cancer · 14
PDF
BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA‐like breast cancers treated with neoadjuvant chemotherapy
2017 · Mamoru Takada, Shigenori Nagai, et al. · Genes Chromosomes and Cancer · 14
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines
2024 · Masaya Hattori, Naoko Honma, et al. · Breast Cancer · 12
PDF
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
2020 · Masato Takahashi, Shoichiro Ohtani, et al. · Breast Cancer Research and Treatment · 10
PDF
A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
2017 · T. Saeki, H. Mukai, et al. · Annals of Oncology · 9
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer
2025 · Tetsuhiro Yoshinami, Yuko Takano, et al. · Breast Cancer · 7
PDF
We’re in this together: Patients’, caregivers’ and health care providers’ illness perceptions about non-small-cell lung cancer (NSCLC)
2015 · Ad A. Kaptein, Kunihiko Kobayashi, et al. · Lung Cancer · 7
Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer
2021 · Katsunori Tozuka, Pattama Wongsirisin, et al. · Scientific Reports · 6
PDF
Works count: 66
Citation count: 897
H-index: 17
I10-index: 21
Year
Topic
Type